CABALETTA BIO, INC. (CABA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $822.08M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $663.78M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $628.98M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $25.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $614.48M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $23.00K.
CABALETTA BIO, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $822.08M | $0.00 | $-611.49M | $210.59M | 3 month · $5.50M |
| 2026-03-31 | $0.00 | $1.00K | $663.78M | $0.00 | $-560.47M | $103.31M | 3 month · $5.26M |
| 2025-12-31 | $0.00 | $1.00K | $628.98M | $25.00K | $-516.96M | $112.05M | 12 month · $20.94M |
| 2025-09-30 | $0.00 | $1.00K | $614.48M | $23.00K | $-475.04M | $139.47M | 3 month · $5.82M |
| 2025-06-30 | $0.00 | $1.00K | $608.65M | $1.00K | $-430.17M | $178.48M | 3 month · $5.71M |
| 2025-03-31 | $0.00 | $1.00K | $506.60M | (m) | $-385.04M | $121.55M | 3 month · $5.16M |
| 2024-12-31 | $0.00 | $1.00K | $501.44M | $0.00 | $-349.10M | $152.34M | 12 month · $19.46M |
| 2024-09-30 | $0.00 | $0.00 | $490.75M | $1.00K | $-316.51M | $174.24M | 3 month · $5.25M |
| 2024-06-30 | $0.00 | $0.00 | $485.43M | $-29.00K | $-285.89M | $199.52M | 3 month · $5.01M |
| 2024-03-31 | $0.00 | $0.00 | $480.04M | $-38.00K | $-258.28M | $221.72M | 3 month · $3.79M |
| 2023-12-31 | $0.00 | $0.00 | $469.40M | $39.00K | $-233.24M | $236.20M | 12 month · $11.34M |
| 2023-09-30 | $0.00 | $0.00 | $373.30M | $-21.00K | $-212.35M | $160.92M | 3 month · $3.01M |
| 2023-06-30 | $0.00 | $0.00 | $370.05M | $-3.00K | $-195.90M | $174.14M | 3 month · $2.80M |
| 2023-03-31 | $0.00 | $0.00 | $273.07M | $0.00 | $-181.42M | $91.65M | 3 month · $2.48M |
| 2022-12-31 | $0.00 | $0.00 | $270.13M | $-47.00K | $-165.56M | $104.52M | 12 month · $6.90M |
| 2022-09-30 | (m) | $0.00 | $235.95M | $-209.00K | $-149.87M | $85.87M | 3 month · $1.73M |
| 2022-06-30 | (m) | $0.00 | $234.22M | $-249.00K | $-138.44M | $95.53M | 3 month · $1.78M |
| 2022-03-31 | (m) | $0.00 | $232.41M | $-152.00K | $-125.53M | $106.72M | 3 month · $1.81M |
| 2021-12-31 | $0.00 | $0.00 | $230.54M | $0.00 | $-112.59M | $117.96M | 12 month · $5.80M |
| 2021-09-30 | (m) | $0.00 | $215.31M | (m) | $-98.70M | $116.61M | 3 month · $1.51M |
| 2021-06-30 | (m) | $0.00 | $188.47M | $1.00K | $-87.14M | $101.33M | 3 month · $1.39M |
| 2021-03-31 | (m) | $0.00 | $179.31M | $3.00K | $-76.00M | $103.31M | 3 month · $1.31M |
| 2020-12-31 | (m) | $0.00 | $175.84M | $6.00K | $-66.30M | $109.54M | 12 month · $4.39M |
| 2020-09-30 | (m) | $0.00 | $174.48M | $12.00K | $-56.99M | $117.50M | 3 month · $1.13M |
| 2020-06-30 | (m) | $0.00 | $173.22M | $11.00K | $-48.60M | $124.64M | 3 month · $1.07M |
| 2020-03-31 | (m) | $0.00 | $172.15M | (m) | $-40.44M | $131.71M | 3 month · $873.00K |
| 2019-12-31 | (m) | $0.00 | $171.28M | (m) | $-32.96M | $138.32M | 12 month · $2.30M |
| 2019-09-30 | (m) | $0.00 | $1.48M | (m) | $-27.56M | $-26.07M | 3 month · $569.00K |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-21.99M | 3 month · $416.00K 6 month · $912.00K |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-19.05M | 3 month · $496.00K |
| 2018-12-31 | (m) | $0.00 | $1.76M | (m) | $-12.45M | $-10.69M | 12 month · $606.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $-10.22M | 3 month · $195.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $-1.14M | 6 month · $131.00K |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-249.00K | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |